2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement …

SS Khan, J Coresh, MJ Pencina, CE Ndumele… - Circulation, 2023 - Am Heart Assoc
Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by
the American Heart Association in response to the high prevalence of metabolic and kidney …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

[HTML][HTML] GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

X Ma, Z Liu, I Ilyas, PJ Little, D Kamato… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
Type 2 diabetes mellitus (T2DM) is closely associated with cardiovascular diseases (CVD),
including atherosclerosis, hypertension and heart failure. Some anti-diabetic medications …

[HTML][HTML] Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes

WD Strain, S Down, P Brown, A Puttanna, A Sinclair - Diabetes Therapy, 2021 - Springer
Prognosis and appropriate treatment goals for older adults with diabetes vary greatly
according to frailty. It is now recognised that changes may be needed to diabetes …

[HTML][HTML] Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials

L Scisciola, V Cataldo, F Taktaz… - Frontiers in …, 2022 - frontiersin.org
Atherosclerosis is a progressive inflammatory disease leading to mortality and morbidity in
the civilized world. Atherosclerosis manifests as an accumulation of plaques in the intimal …

[HTML][HTML] Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor …

N D'Onofrio, C Sardu, MC Trotta, L Scisciola… - Molecular …, 2021 - Elsevier
Objective We evaluated sodium-glucose co-transporter2 (SGLT2) expression and the effect
of SGLT2 inhibitor (SGLT2i) therapies on carotid plaques of asymptomatic diabetic and non …

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational …

S Kohsaka, CSP Lam, DJ Kim… - The Lancet Diabetes & …, 2020 - thelancet.com
Background Cardiovascular outcome trials have shown cardiovascular benefit with sodium-
glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas …

[HTML][HTML] Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence

A Natali, L Nesti, D Tricò, E Ferrannini - Cardiovascular Diabetology, 2021 - Springer
The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …

[HTML][HTML] Therapy of type 2 diabetes

R Landgraf, J Aberle, AL Birkenfeld… - Experimental and …, 2019 - thieme-connect.com
The practical recommendations of the German Diabetes Society/Deutsche Diabetes
Gesellschaft (DDG) together with the German Society for Internal Medicine/Deutschen …